

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/12, C07K 14/705, C12N 15/62, C07K 16/00, C12N 5/10, A61K 35/12

(11) International Publication Number:

WO 97/23613

(43) International Publication Date:

3 July 1997 (03.07.97)

(21) International Application Number:

PCT/GB96/03209

A2

(22) International Filing Date:

23 December 1996 (23.12.96)

(30) Priority Data:

9526131.9

21 December 1995 (21.12.95)

(71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LTD. [GB/GB]; 216 Bath Road. Slough, Berkshire SLI 4EN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEBBINGTON, Christopher, Robert [GB/GB]; Berry Cottage, Westbrook, Boxford. Newbury, Berkshire RG20 8DJ (GB). LAWSON, Alastair. David, Griffiths [GB/GB]; Holden Farm, Cheriton, Alresford, Hants. SO240NX (GB), WEIR, Andrew, Neil, Charles [GB/GB]; 7 Willow Drive, Twyford, Berkshire RG10 9DD (GB), FINNEY, Helene, Margaret [GB/GB], 64 Clare Road, Maidenhead, Berkshire SL6 4DQ (GB).

(74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT. RO. RU. SD. SE. SG. SI. SK. TJ. TM. TR. TT. UA. UG. US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

## Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CELL ACTIVATION PROCESS AND REAGENTS THEREFOR

(57) Abstract

A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components. The activated cell may be of use in medicine for example in the treatment of